476 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
26
Ending by 2030
Jan 2027
Next term end
106
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2033 · High confidence
Also notable
Ends Aug 2036 · High confidence
Also notable
Ends Nov 2036 · High confidence
Also notable
Ends Oct 2029 · High confidence
Also notable
Ends Jun 2035 · Medium confidence
Also notable
Ends Mar 2036 · High confidence
Also notable
Ends Jul 2028 · High confidence
Also notable
Ends Mar 2036 · High confidence
Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
US 9,101,585
Cited by 129 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Prostate Cancer and Other Cancers
US 11,826,409
Cited by 17 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Small Cell Lung Cancer and Other Cancers
US 10,253,077
Cited by 93 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2036.
Novel Immunotherapy Against Several Tumors Including Neuronal and Brain Tumors
US 10,227,381
Cited by 50 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2029.
Personalized Immunotherapy Against Several Neuronal and Brain Tumors
US 11,607,446
Cited by 28 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2035.
Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Tumors
US 11,702,460
Cited by 19 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Novel Immunotherapy Against Neuronal and Brain Tumors
US 10,420,800
Cited by 119 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2028.
Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Tumors
US 10,450,362
Cited by 27 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2036.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Nov 21 to 23, 2026 · next Nov 21
- 14 fees due Dec 6 to 27, 2026 · next Dec 6
- 15 fees due Jan 2 to 30, 2027 · next Jan 2
- 19 fees due Feb 6 to 27, 2027 · next Feb 6
- 7 fees due Mar 3 to 24, 2027 · next Mar 3
- 22 fees due Apr 8 to 30, 2027 · next Apr 8
- 23 fees due May 3 to 28, 2027 · next May 3
- 12 fees due Jun 3 to 30, 2027 · next Jun 3
- 20 fees due Jul 2 to 30, 2027 · next Jul 2
- 17 fees due Aug 4 to 27, 2027 · next Aug 4
- 22 fees due Sep 3 to 26, 2027 · next Sep 3
- 15 fees due Oct 2 to 30, 2027 · next Oct 2
- 8 fees due Nov 5 to 19, 2027 · next Nov 5
Recent changes
- 35 terms have ended since Aug 22, 2026
- Nov 17 US 7,807,642 Tumor-Associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules · term ended
- Nov 17 US 10,196,432 Tumor-Associated Peptides Binding to Human Leukocyte Antigen (HLA) Class II Molecules · term ended
- Oct 23 US 10,106,594 Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Tumors · lapsed on the fee record
- Oct 23 US 10,106,593 Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Tumors · lapsed on the fee record
- Oct 23 US 10,105,428 Novel peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers · lapsed on the fee record
- Oct 16 US 7,811,828 Method for Identifying and Quantifying of Tumour-Associated · term ended
- Oct 16 US 10,100,085 Novel Immunotherapy Against Several Tumors Including Neuronal and Brain Tumors · lapsed on the fee record
- Oct 16 US 10,098,938 Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Cancers · lapsed on the fee record
- Oct 16 US 10,098,937 Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Cancers · lapsed on the fee record
- Oct 11 US 11,466,072 Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Tumors · lapsed on the fee record
- Oct 9 US 10,093,715 Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Tumors · lapsed on the fee record
- Oct 4 US 11,459,371 Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Tumors · lapsed on the fee record
- Oct 4 US 11,459,366 Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, SCLC and Other Cancers · lapsed on the fee record
- Oct 4 US 11,459,365 Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including Nsclc, SCLC and Other Cancers · lapsed on the fee record
- Sep 25 US 10,081,665 Novel Peptides and Combination of Peptides for Use in Immunotherapy Against Various Tumors · lapsed on the fee record
What they patent
The largest of its 106 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,008,431 | Tumor-Associated Peptides That Bind to Mhc-Molecules In force · High confidence | In force | High confidence | |
| US 7,833,969 | Tumor-Associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules In force · High confidence | In force | High confidence | |
| US 7,833,970 | Tumor-Associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules In force · High confidence | In force | High confidence | |
| US 7,968,097 | Identification of HLA-A2-PRESENTED T-Cell Epitopes Derived from the Oncofoetal Antigen-Immature Laminin Receptor Protein and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,308,244 | Combination Therapy Using Active Immunotherapy In force · High confidence | In force | High confidence | |
| US 9,511,128 | Novel Immunogenic Epitopes for Immunotherapy In force · High confidence | In force | High confidence | |
| US 10,420,800 | Novel Immunotherapy Against Neuronal and Brain Tumors In force · High confidence | In force | High confidence | |
| US 10,434,120 | Novel Immunotherapy Against Neuronal and Brain Tumors In force · High confidence | In force | High confidence | |
| US 10,709,735 | Novel Immunotherapy Against Neuronal and Brain Tumors In force · High confidence | In force | High confidence | |
| US 11,648,276 | Novel Immunotherapy Against Neuronal and Brain Tumors In force · High confidence | In force | High confidence |
Also on record, not counted in the 476: 2 patents in force now held by others · 257 patents ended · 91 applications pending · 197 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.